Deferasirox desensitization

Given that deferasirox is the only oral iron chelator approved for pediatric use in the United States and that maculopapular rash is a known adverse reaction of the medication, it leaves pediatric patients with deferoxamine as their only other option for iron chelation therapy. Deferasirox desensiti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2016-01, Vol.4 (1), p.171-172
Hauptverfasser:	Bruner, Karen E., MD, White, Kevin M., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Aged Allergens - immunology Allergy and Immunology Benzoates - immunology Benzoates - therapeutic use Blood Transfusion Blood transfusions Chelation therapy Child Desensitization, Immunologic - methods Drug Eruptions - immunology Drug Eruptions - therapy Epidemics FDA approval Female Humans Immunoglobulins Internal Medicine Iron Chelating Agents - therapeutic use Iron Overload - drug therapy Iron Overload - etiology Male Patients Pediatrics Postoperative Complications - drug therapy Triazoles - immunology Triazoles - therapeutic use Withholding Treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Given that deferasirox is the only oral iron chelator approved for pediatric use in the United States and that maculopapular rash is a known adverse reaction of the medication, it leaves pediatric patients with deferoxamine as their only other option for iron chelation therapy. Deferasirox desensitization may allow patients an improved quality of life and increase medication compliance for the treatment of iron overload.
ISSN:	2213-2198 2213-2201
DOI:	10.1016/j.jaip.2015.09.007